Research graph
References from Overall survival with immune checkpoint inhibitors across treatment settings and clinical and PD-L1-defined subgroups in advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of randomized trials. Local targets link to admitted publications; unresolved targets remain external evidence.
The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040
10.1053/j.gastro.2022.05.054 · 2022 · External reference
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21834 · 2024 · External reference
Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2022.07.003 · 2022 · External reference
Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology
10.6004/jnccn.2023.0019 · 2023 · External reference
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
10.3389/fimmu.2022.964442 · 2022 · External reference
Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma
10.1056/nejmoa2111380 · 2022 · External reference
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
10.1016/s1470-2045(19)30626-6 · 2019 · External reference
Effectiveness of immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma: A meta-analysis including low PD-L1 subgroups
10.1001/jamaoncol.2022.5816 · 2023 · External reference
Current evidence of PD-1 and PD-L1 immune checkpoint inhibitors for esophageal cancer: an updated meta-analysis and synthesis of ongoing clinical trials
10.1177/17588359231221339 · 2024 · External reference
PD-1/PD-L1 inhibitors in advanced, unresectable esophageal squamous-cell carcinoma: A meta-analysis of their effects across patient subgroups
10.1016/j.critrevonc.2025.104876 · 2025 · External reference
Beneficial subgroups for PD-1 inhibitor plus chemotherapy in first-line treatment of advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis
10.1097/md.0000000000047981 · 2026 · External reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
10.1136/bmj.n71 · 2021 · External reference
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial
10.1002/cam4.7235 · 2024 · External reference
Correction to "Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial
10.1002/cam4.70652 · 2025 · External reference
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
10.1016/s0140-6736(21)01234-4 · 2021 · External reference
Department of error
10.1016/s0140-6736(21)02487-9 · 2021 · External reference
Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study
10.1016/j.esmoop.2025.105854 · 2025 · External reference
Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial
10.1001/jama.2021.12836 · 2021 · External reference
Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial
10.1016/j.medj.2024.05.008 · 2024 · External reference
First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study
10.1038/s41591-024-02797-y · 2024 · External reference
Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s1470-2045(25)00401-2 · 2026 · External reference
First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial
10.1038/s41591-022-02179-2 · 2023 · External reference
The effect of liver metastases on clinical efficacy of first-line programmed death-1 inhibitor plus chemotherapy in esophageal squamous cell carcinoma: A post hoc analysis of ASTRUM-007 and meta-analysis
10.1002/cam4.7203 · 2024 · External reference
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial
10.1016/j.ccell.2022.02.007 · 2022 · External reference
Clinical benefit of first-line programmed death-1 antibody plus chemotherapy in low programmed cell death ligand 1-expressing esophageal squamous cell carcinoma: A post hoc analysis of JUPITER-06 and meta-analysis
10.1200/jco.22.01490 · 2023 · External reference
Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase III trial of toripalimab plus chemotherapy in advanced esophageal squamous-cell carcinoma
10.1016/j.annonc.2026.01.005 · 2026 · External reference
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
10.1136/bmj-2021-068714 · 2022 · External reference
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
10.1016/s1470-2045(23)00108-0 · 2023 · External reference
First-line tislelizumab plus chemotherapy for esophageal squamous cell carcinoma with programmed death-ligand 1 expression ≥ 1%: A retrospective analysis of RATIONALE-306
10.1007/s12325-025-03115-9 · 2025 · External reference
Correction to lancet oncol 2019; 20: 1506–517
10.1016/s1470-2045(19)30646-1 · 2019 · External reference
Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3)
10.1007/s10388-020-00794-x · 2021 · External reference
Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3)
10.1158/1078-0432.ccr-21-0985 · 2022 · External reference
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
10.1016/s1470-2045(20)30110-8 · 2020 · External reference
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)
10.1038/s41467-022-28408-3 · 2022 · External reference
Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer
10.1200/jco.20.01888 · 2020 · External reference
Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia
10.1016/j.esmoop.2021.100341 · 2022 · External reference
Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181
10.1007/s10388-021-00877-3 · 2022 · External reference
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): A randomized phase III study
10.1200/jco.21.01926 · 2022 · External reference
Erratum: tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): A randomized phase III study
10.1200/jco.23.02629 · 2024 · External reference
Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study
10.1016/j.esmoop.2023.102202 · 2024 · External reference
Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302
10.1007/s10388-023-01040-w · 2024 · External reference
RoB 2: a revised tool for assessing risk of bias in randomised trials
10.1136/bmj.l4898 · 2019 · External reference
The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method
10.1186/1471-2288-14-25 · 2014 · External reference
Conducting meta-analyses in R with the metafor package
10.18637/jss.v036.i03 · 2010 · External reference
